The earnings call reflects a positive outlook for Genmab, with strong financial performance and successful pipeline advancements, particularly with EPKINLY and Rina-S. The company faces some competitive and regulatory challenges, but the overall momentum and strategic execution support a positive sentiment.

Company Guidance -

Q3 2025

In the recent Genmab First Half 2025 Financial Results Conference Call, the company reported a 19% increase in total revenue, driven by a 56% growth in operating profit despite strategic investments. Genmab ended the first half with around $3 billion in cash, highlighting financial strength and flexibility for future growth. Key drug developments included Epcoritamab, which is anticipated to generate over $3 billion in peak sales, and Rina-S, expected to exceed $2 billion in sales. The FDA accepted a priority review for Epcoritamab's sBLA, targeting a November 2025 action date. Genmab's commercial products, EPKINLY and Tivdak, saw a 60% increase in sales, contributing 31% to total revenue growth. Operating expenses rose by 6% to just under $1 billion, with a net profit of $531 million reported. The company updated its 2025 financial guidance, projecting 15% revenue growth and a 26% increase in operating profit, demonstrating strong financial health and strategic focus on high-impact programs.

Strong Financial Performance

Genmab reported a 19% increase in total revenue, driven by a 27% growth in recurring revenue. Operating profit grew by 56%, and the company ended the first half with around $3 billion in cash. The improved guidance projects a 15% revenue growth for the year.

Positive Phase III Results for EPCORE FL-1

The EPCORE FL-1 trial met its dual primary endpoints of overall response rate and progression-free survival, reducing the risk of disease progression or death by 79%. These results will support global regulatory submissions.

Expanding Market for EPKINLY and Tivdak

Sales for EPKINLY and Tivdak increased by 60% year-over-year, contributing to 31% of total revenue growth. EPKINLY posted $211 million in global sales, a 74% year-over-year increase.

Pipeline Advancements

Rina-S showed promising results in advanced endometrial cancer with a confirmed ORR of 50%. Plans are underway for additional Phase III trials in both ovarian and endometrial cancers.

Genmab (GMAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GMAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.44 / -	0.287	―	―	―
Aug 07, 2025	2025 (Q2)	0.40 / 0.54	0.317	70.98% (+0.23)
May 08, 2025	2025 (Q1)	0.23 / 0.30	0.292	4.45% (+0.01)
Feb 12, 2025	2024 (Q4)	0.37 / 0.85	0.139	512.23% (+0.71)
Nov 06, 2024	2024 (Q3)	0.31 / 0.29	0.464	-38.15% (-0.18)
Aug 08, 2024	2024 (Q2)	0.31 / 0.32	0.305	3.93% (+0.01)
May 02, 2024	2024 (Q1)	0.19 / 0.29	0.05	484.00% (+0.24)
Feb 14, 2024	2023 (Q4)	0.31 / 0.14	0.125	11.20% (+0.01)
Nov 07, 2023	2023 (Q3)	0.33 / 0.46	0.528	-12.12% (-0.06)
Aug 03, 2023	2023 (Q2)	0.29 / 0.30	0.399	-23.56% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GMAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.51	$22.69	+5.49%
May 08, 2025	$20.60	$19.42	-5.73%
Feb 12, 2025	$18.89	$19.69	+4.24%
Nov 06, 2024	$22.75	$22.33	-1.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genmab A/S (GMAB) report earnings?

Genmab A/S (GMAB) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Genmab A/S (GMAB) earnings time?

Genmab A/S (GMAB) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GMAB EPS forecast?

GMAB EPS forecast for the fiscal quarter 2025 (Q3) is 0.44.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing